4 chapters across the catalog
Recent reports in The Atlantic suggest that the science behind Ozempic and other GLP-1 drugs may be misunderstood, as the weight-loss effects appear to be driven by the brain rather than the gut. These drugs cross the blood-brain barrier and may affect addictive behaviors, though scientists admit they do not fully understand the long-term consequences. Despite this, prescriptions have increased 400% since 2019, with the industry projected to reach $100 billion by 2030.
Entyvio Commercial Warnings, PML Brain Infection
The hosts deconstruct a commercial for the Crohn's disease drug Entyvio, which includes a warning for a rare, fatal brain infection called PML. They note the disclaimer states the condition has "not been reported" with the drug, leading them to wonder why the warning is included. They discuss a theory that more horrific warnings actually increase consumer interest in pharmaceutical products.
A clinical drug trial in Rennes, France, results in one person being declared brain dead and five others hospitalized. The drug, intended to target the endocannabinoid system for pain management, likely caused the neurological damage due to a massive dosage error or "hot dose" during the testing phase.
Binary Triggers, Psychotropic Drugs, Media Glitches
The hosts discuss the possibility of "binary triggers" where a combination of psychotropic drugs and specific stimuli in video games could activate a person. They reference past instances of news reporters speaking gibberish on air as potential tests of this technology. They suggest that modern frequencies like LTE and 4G might be unintentionally interfering with human brain waves.
